Case Report Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 6, 2024; 12(16): 2876-2880
Published online Jun 6, 2024. doi: 10.12998/wjcc.v12.i16.2876
Uterine epithelioid trophoblastic tumor with the main manifestation of increased human chorionic gonadotropin: A case report
Li-Na Huang, Department of Gynecology, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China
Xi Deng, Department of Ningbo Clinical Pathology Diagnosis Center, Ningbo 315021, Zhejiang Province, China
Jian Xu, Department of Imaging, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China
ORCID number: Li-Na Huang (0000-0003-4111-9756).
Author contributions: Huang LN conducted the studies, collected data, and drafted the manuscript; Deng X and Xu J participated in acquiring, analyzing, or interpreting data and drafting the manuscript. All authors have read and approve the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Na Huang, MS, Department of Gynecology, Ningbo Women and Children's Hospital, No. 339 Liuting Street, Haishu District, Ningbo 315012, Zhejiang Province, China. hln314@163.com
Received: January 31, 2024
Revised: April 3, 2024
Accepted: April 18, 2024
Published online: June 6, 2024
Processing time: 118 Days and 23.1 Hours

Abstract
BACKGROUND

Epithelioid trophoblastic tumor (ETT) is an extremely rare malignant gestational trophoblastic neoplasm commonly presenting with abnormal vaginal bleeding, abdominal pain, and increased human chorionic gonadotropin (hCG). This study reported a case of uterine ETT with the main manifestation being increased hCG.

CASE SUMMARY

A 39-year-old female was referred to the Ningbo Maternal and Child Hospital of China in December 2022, complaining of increased hCG levels for 1 month. Magnetic resonance imaging revealed gestational trophoblastic tumor, and hysteroscopic electrotomy and curettage of intrauterine hyperplasia were performed. The patient was diagnosed with uterine ETT through postoperative pathological examination and immunohistochemical results. Total laparoscopic hysterectomy and bilateral salpingectomy were performed, and hCG levels returned to normal. The patient was without recurrence during the postoperative 3-month follow-up.

CONCLUSION

This study reported a case of uterine ETT with the main manifestation being increased hCG, highlighting that ETT should be considered in the presence of abnormal hCG. A total laparoscopic hysterectomy is recommended.

Key Words: Uterine epithelioid trophoblastic tumor, Gestational trophoblastic neoplasm, Diagnosis, Human chorionic gonadotropin, Case report

Core Tip: This study presents a rare case of uterine epithelioid trophoblastic tumor (ETT) with elevation of human chorionic gonadotropin (hCG) as the only sign. The patient, initially misdiagnosed with gestational trophoblastic tumor, underwent a successful total laparoscopic hysterectomy, emphasizing the significance of considering ETT in cases with abnormal hCG. The study highlights the diagnostic challenges posed by ETT and advocates for total laparoscopic hysterectomy as a recommended treatment, contributing valuable insights for gynecologists facing similar cases.



INTRODUCTION

An epithelioid trophoblastic tumor (ETT) originates from chorionic-type intermediate trophoblast cells and occurs mainly in women of childbearing age, accounting for 1%-2% of gestational trophoblastic neoplasm (GTN)[1]. The ETT lesions most commonly occur in the corpus uterus, followed by the cervix uteri and lungs, while a few cases occur in other pelvic and abdominal organs such as the vagina, oviduct, intestinal tract, and liver[2]. ETT commonly presents with abnormal vaginal bleeding, abdominal pain, and normal or mildly increased human chorionic gonadotropin (hCG). Due to the rare occurrence of the disease and the lack of specific clinical manifestations, ETT is very difficult to diagnose. This study reported a case of uterine ETT with the main manifestation being increased hCG.

CASE PRESENTATION
Chief complaints

A 39-year-old female was referred to the Ningbo Maternal and Child Hospital of China in December 2022, complaining of increased hCG levels for 1 month.

History of present illness

hCG was 49.21 IU/L at admission. The patient denied any other complaints.

History of past illness

The patient underwent curettage for hydatidiform mole in 2006.

Personal and family history

The patient had undergone two full-term cesarean deliveries in 2010 and 2016, respectively. The patient had no relevant family history.

Physical examination

The physical examination was unremarkable and normal.

Laboratory examinations

hCG was 49.21 IU/L at admission.

Imaging examinations

The color Doppler flow imaging of the uterus showed a 21 mm × 7 mm × 20 mm hypoechoic area in the anterior uterine wall with a well-circumscribed margin and a rich blood flow signal (resistance index: 0.46). Magnetic resonance imaging showed roundish long T1 and slightly short T2 signals of 19 mm × 19 mm × 16 mm in the anterior uterine wall (Figure 1), which suggested a GTN.

Figure 1
Figure 1 Magnetic resonance imaging of the uterine epithelioid trophoblastic tumor. A: T2 weighted image (T2WI) coronal view of a mixed T2WI iso-signal nodular mass (arrow) in the myometrium of the left anterior wall of the uterus with local protrusion into the uterine cavity; B: T2WI pectral attenuated onversion recovery (SPAIR) in axial position with a mixed iso-signal mass (arrow); C: T1 weighted image SPAIR-enhanced coronal view with an inhomogeneous enhancement of the mass (arrow).
FINAL DIAGNOSIS

Hysteroscopic electrotomy and curettage of intrauterine hyperplasia were performed. Postoperative pathological examination showed endometrial hyperplastic and intrauterine malignant tumor. Immunohistochemical results showed diffuse positivity for GATA-3, CK (pan), and CD146 and focal positivity for β-hCG, human placental lactogen (hPL), and α-inhibin. Nuclear staining of Ki-67 and P63 was seen (Figure 2). Therefore, the patient was diagnosed with uterine ETT.

Figure 2
Figure 2 Immunohistochemical findings of uterine epithelioid trophoblastic tumor. A: Hematoxylin and eosin (HE) (× 10), the tumor cells were arranged in nested clusters, and a large map-like necrosis was seen in the center of the neoplastic nests, marked with an asterisk; B: HE (× 20), most of the tumor cells were uniform in size and showed epithelial-like morphology (black triangle): The cells were polygonal with clear borders, abundant cytoplasm, and eosinophilic, clear cell membrane, rounded and centered nuclei with obvious small nucleoli, and occasional nuclear fission images; C: Immunohistochemistry (IHC) (× 10), tumor cells express β-human chorionic gonadotropin; D: IHC (× 10), tumor cells expressed α-inhibin; E: IHC (× 5), tumor cells expressed p63; F: IHC (× 10), tumor cells Ki-67 proliferation index was about 60%.
TREATMENT

Total laparoscopic hysterectomy and bilateral salpingectomy were performed. Postoperative pathology showed tumor residues (infiltrating < 1/2 fibromuscular wall) between the local muscle wall of the uterus, and the maximum diameter of the residual tumor was about 0.6 cm under the microscope.

OUTCOME AND FOLLOW-UP

The hCG levels returned to normal, and the patient did not recur during the postoperative 3-month follow-up.

DISCUSSION

ETT typically presents with atypical symptoms, such as vaginal bleeding or abdominal pain, but these features were not observed in the present case, posing a challenge to the initial diagnosis. The diagnosis of ETT mainly relies on histopathology and immunohistochemistry. Immunohistochemistry can be used to differentiate ETT from other types of GTN, and the important immunohistochemical markers include p63, α-inhibin, β-hCG, GATA3, hPL, PLAP, and the Ki67 proliferation index[3], consistent with the findings in the case reported here.

Currently, the primary treatment for ETT is hysterectomy, which is recommended for patients with lesions confined to the uterus and no requirement for fertility preservation[4]. In a retrospective review, five women with ETT were cured by hysterectomy[5]. One study reported a case that underwent hysteroscopic resection with uterus preservation and found no recurrence at the 16-month follow-up[6]. For lesions confined to the uterus, complete hysterectomy or extensive resection of lesions can completely alleviate the disease[7]. Considering the strong concealed of ETT, surgery with preservation of reproductive function is generally not recommended[8]. The patient’s hCG decreased to normal after hysteroscopic electrosurgical and curettage of intrauterine hyperplasia, while the pathological results of the specimen showed tumor residue in the endometrial myometrium, indicating that normal hCG after surgery and residual lesion may coexist, and preservation of the uterus should be considered with caution.

The preoperative assessment of the patient indicated that the uterus was of normal size and could be fully extracted vaginally. Therefore, laparoscopic surgery was selected. In cases where the uterus is enlarged and cannot be fully extracted vaginally, open abdominal surgery is still recommended, or protective measures should be taken to remove the specimen (such as placing it in a sealed specimen bag and extracting it through a vaginal incision). The use of a morcellator should be avoided to prevent iatrogenic tumor dissemination and implantation[9-11].

ETT should be considered in the presence of abnormal hCG levels. A total laparoscopic hysterectomy is recommended.

CONCLUSION

This study reported a case of ETT, the main manifestation of which was increased hCG, providing valuable experience in the diagnosis and treatment of ETT for clinical gynecologists.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medicine, research and experimental

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Mohey NM, Egypt S-Editor: Liu H L-Editor: A P-Editor: Zhang YL

References
1.  Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol. 2017;144:208-214.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 66]  [Cited by in F6Publishing: 76]  [Article Influence: 9.5]  [Reference Citation Analysis (0)]
2.  Jordan S, Randall LM, Karamurzin Y, Ward P, Lin F, Brewster W, Monk BJ. Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor. Int J Gynecol Cancer. 2011;21:918-922.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 17]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
3.  Sung WJ, Shin HC, Kim MK, Kim MJ. Epithelioid trophoblastic tumor: clinicopathologic and immunohistochemical analysis of three cases. Korean J Pathol. 2013;47:67-73.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
4.  Davis MR, Howitt BE, Quade BJ, Crum CP, Horowitz NS, Goldstein DP, Berkowitz RS. Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 2015;137:456-461.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 50]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
5.  Sobecki-Rausch J, Winder A, Maniar KP, Hoekstra AV, Berry E, Novak K, Lurain JR. Surgery and Platinum/Etoposide-Based Chemotherapy for the Treatment of Epithelioid Trophoblastic Tumor. Int J Gynecol Cancer. 2018;28:1117-1122.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 12]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
6.  Li J, Shi Y, Wan X, Qian H, Zhou C, Chen X. Epithelioid trophoblastic tumor: a clinicopathological and immunohistochemical study of seven cases. Med Oncol. 2011;28:294-299.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 25]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
7.  Yang J, Zong L, Wang J, Wan X, Feng F, Xiang Y. Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. J Cancer. 2019;10:11-19.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 28]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
8.  Jiang F, Xiang Y. [Deeper understanding of epithelioid trophoblastic tumor]. Xiehe Yixue Zazhi. 2018;9:31-35.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 327]  [Cited by in F6Publishing: 783]  [Article Influence: 195.8]  [Reference Citation Analysis (0)]
10.  Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N; ESMO Guidelines Committee. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:860-877.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 153]  [Article Influence: 76.5]  [Reference Citation Analysis (0)]
11.  Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede CD, Pather S, Simcock B, Farrell R, Robertson G, Walker G, Armfield NR, Graves N, McCartney AJ, Obermair A. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017;317:1224-1233.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 199]  [Cited by in F6Publishing: 215]  [Article Influence: 30.7]  [Reference Citation Analysis (0)]